Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy
复制标题
DOI：
10.1086/378808
复制
发表时间：
2003-11-01
影响因子：
11.8
通讯作者：
Butel, JS
中科院分区：
文献类型：
--
作者：
Ling, PD;Vilchez, RA;Butel, JS
人类免疫缺陷病毒1型（HIV-1）感染的患者发生EB病毒（EBV）相关淋巴瘤的风险很高。然而，人们对接受高效抗逆转录病毒治疗（HAART）的患者的EBV DNA载量知之甚少。使用实时定量聚合酶链反应分析，我们证明了接受HAART的HIV-1感染患者比未感染HIV-1的志愿者血液中可检测到EBV DNA的显著更多（70例患者中的57例[81%] vs. 68例患者中的11例[16%]; P = 0.001）和唾液（68例患者中的55例[79%] vs. 68例患者中的37例[54%]; P = 0.002）。HIV-1感染患者的血液和唾液样本中的平均EBV载量也高于未感染HIV-1的志愿者（P =.001）。在HIV-1感染者中，血液中EBV检测频率与较低的CD4（+）细胞计数相关（P =.03），尽管在HIV-1感染组的血液或唾液样本中没有观察到EBV DNA载量的差异。需要进一步的研究来确定EBV特异性CD4（+）和CD8（+）细胞是否在接受HAART的HIV-1感染患者的EBV发病机制中发挥作用。
Patients with human immunodeficiency virus type 1 (HIV-1) infection are at high risk of developing Epstein-Barr virus (EBV)-associated lymphoma. However, little is known of the EBV DNA loads in patients receiving highly active antiretroviral therapy (HAART). Using a real-time quantitative polymerase chain reaction assay, we demonstrated that significantly more HIV-1-infected patients receiving HAART than HIV-1-uninfected volunteers had detectable EBV DNA in blood (57 [81%] of 70 vs. 11 [16%] of 68 patients; P = .001) and saliva (55 [79%] of 68 vs. 37 [54%] of 68 patients; P = .002). The mean EBV loads in blood and saliva samples were also higher in HIV-1-infected patients than in HIV-1-uninfected volunteers (P = .001). The frequency of EBV detection in blood was associated with lower CD4(+) cell counts (P = .03) among HIV-1-infected individuals, although no differences were observed in the EBV DNA loads in blood or saliva samples in the HIV-1-infected group. Additional studies are needed to determine whether EBV-specific CD4(+) and CD8(+) cells play a role in the pathogenesis of EBV in HIV-1-infected patients receiving HAART.